BACKGROUND: Most HIV-1 transmission in Africa occurs among HIV-1-discordant couples (one partner HIV-1 infected and one uninfected) who are unaware of their discordant HIV-1 serostatus. Given the high HIV-1 incidence among HIV-1 discordant couples and to assess efficacy of interventions for reducing HIV-1 transmission, HIV-1 discordant couples represent a critical target population for HIV-1 prevention interventions and prevention trials. Substantial regional differences exist in HIV-1 prevalence in Africa, but regional differences in HIV-1 discordance among African couples, has not previously been reported. METHODOLOGY/PRINCIPAL FINDINGS: The Partners in Prevention HSV-2/HIV-1 Transmission Trial ("Partners HSV-2 Study"), the first large HI...
INTRODUCTION: Objective was to examine the temporal variation of HIV sero-discordancy in select repr...
BACKGROUND: In order to inform prevention programming, we analyzed HIV discordance and concordance w...
The Partners HSV-2/HIV-1 Transmission Study (Partners Study) is a phase III, placebo-controlled tria...
Background: Most HIV-1 transmission in Africa occurs among HIV-1-discordant couples (one partner HIV...
Introduction: In sub-Saharan Africa where HIV/AIDS epidemic is predominantly generalized, majority ...
OBJECTIVE: To describe patterns of HIV infection among stable sexual partnerships across sub-Saharan...
BACKGROUND: The Partners HSV-2/HIV-1 Transmission Study (Partners Study) is a phase III, placebo-con...
BACKGROUND: The Partners HSV-2/HIV-1 Transmission Study (Partners Study) is a phase III, placebo-con...
BACKGROUND: Early initiation of antiretroviral therapy reduces risk of transmission to the uninfecte...
HIV epidemiology informs prevention trial design and program planning. Nine clinical research center...
INTRODUCTION:More new HIV-1 infections occur within stable HIV-1-discordant couples than in any othe...
HIV epidemiology informs prevention trial design and program planning. Nine clinical research center...
Background: Representative and precise estimates for the annual risk of HIV transmission (ϕ) from th...
Background Persons living with HIV (PLWH) who are members of sero-discordant and ser...
More new HIV-1 infections occur within stable HIV-1-discordant couples than in any other group in Af...
INTRODUCTION: Objective was to examine the temporal variation of HIV sero-discordancy in select repr...
BACKGROUND: In order to inform prevention programming, we analyzed HIV discordance and concordance w...
The Partners HSV-2/HIV-1 Transmission Study (Partners Study) is a phase III, placebo-controlled tria...
Background: Most HIV-1 transmission in Africa occurs among HIV-1-discordant couples (one partner HIV...
Introduction: In sub-Saharan Africa where HIV/AIDS epidemic is predominantly generalized, majority ...
OBJECTIVE: To describe patterns of HIV infection among stable sexual partnerships across sub-Saharan...
BACKGROUND: The Partners HSV-2/HIV-1 Transmission Study (Partners Study) is a phase III, placebo-con...
BACKGROUND: The Partners HSV-2/HIV-1 Transmission Study (Partners Study) is a phase III, placebo-con...
BACKGROUND: Early initiation of antiretroviral therapy reduces risk of transmission to the uninfecte...
HIV epidemiology informs prevention trial design and program planning. Nine clinical research center...
INTRODUCTION:More new HIV-1 infections occur within stable HIV-1-discordant couples than in any othe...
HIV epidemiology informs prevention trial design and program planning. Nine clinical research center...
Background: Representative and precise estimates for the annual risk of HIV transmission (ϕ) from th...
Background Persons living with HIV (PLWH) who are members of sero-discordant and ser...
More new HIV-1 infections occur within stable HIV-1-discordant couples than in any other group in Af...
INTRODUCTION: Objective was to examine the temporal variation of HIV sero-discordancy in select repr...
BACKGROUND: In order to inform prevention programming, we analyzed HIV discordance and concordance w...
The Partners HSV-2/HIV-1 Transmission Study (Partners Study) is a phase III, placebo-controlled tria...